Apeloa Pharmaceutical Co Ltd (000739) - Total Liabilities
Based on the latest financial reports, Apeloa Pharmaceutical Co Ltd (000739) has total liabilities worth CN¥5.68 Billion CNY (≈ $831.31 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Apeloa Pharmaceutical Co Ltd - Total Liabilities Trend (1994–2025)
This chart illustrates how Apeloa Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 000739 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Apeloa Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Apeloa Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taseko Mines Ltd
TO:TKO
|
Canada | CA$1.75 Billion |
|
Eurazeo
PA:RF
|
France | €1.70 Billion |
|
Northeast Securities Co Ltd
SHE:000686
|
China | CN¥106.26 Billion |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
China | CN¥10.29 Billion |
|
IHS Holding Ltd
NYSE:IHS
|
USA | $4.69 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $112.59 Million |
|
Treasury Wine Estates Ltd
AU:TWE
|
Australia | AU$3.00 Billion |
|
Steadfast Group Limited
F:1S6
|
Germany | €3.80 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Apeloa Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Apeloa Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apeloa Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apeloa Pharmaceutical Co Ltd (1994–2025)
The table below shows the annual total liabilities of Apeloa Pharmaceutical Co Ltd from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥5.97 Billion ≈ $873.88 Million |
-0.12% |
| 2024-12-31 | CN¥5.98 Billion ≈ $874.93 Million |
-8.54% |
| 2023-12-31 | CN¥6.54 Billion ≈ $956.60 Million |
+0.54% |
| 2022-12-31 | CN¥6.50 Billion ≈ $951.46 Million |
+63.18% |
| 2021-12-31 | CN¥3.98 Billion ≈ $583.08 Million |
+28.37% |
| 2020-12-31 | CN¥3.10 Billion ≈ $454.23 Million |
+12.69% |
| 2019-12-31 | CN¥2.75 Billion ≈ $403.08 Million |
+14.46% |
| 2018-12-31 | CN¥2.41 Billion ≈ $352.15 Million |
-8.88% |
| 2017-12-31 | CN¥2.64 Billion ≈ $386.48 Million |
-12.03% |
| 2016-12-31 | CN¥3.00 Billion ≈ $439.35 Million |
+0.82% |
| 2015-12-31 | CN¥2.98 Billion ≈ $435.80 Million |
+8.07% |
| 2014-12-31 | CN¥2.76 Billion ≈ $403.27 Million |
-1.73% |
| 2013-12-31 | CN¥2.80 Billion ≈ $410.38 Million |
+2.29% |
| 2012-12-31 | CN¥2.74 Billion ≈ $401.19 Million |
+14.46% |
| 2011-12-31 | CN¥2.40 Billion ≈ $350.49 Million |
+131.20% |
| 2010-12-31 | CN¥1.04 Billion ≈ $151.60 Million |
+8.49% |
| 2009-12-31 | CN¥954.91 Million ≈ $139.73 Million |
-1.86% |
| 2008-12-31 | CN¥973.00 Million ≈ $142.38 Million |
+12.61% |
| 2007-12-31 | CN¥864.02 Million ≈ $126.43 Million |
+4.26% |
| 2006-12-31 | CN¥828.68 Million ≈ $121.26 Million |
+13.06% |
| 2005-12-31 | CN¥732.94 Million ≈ $107.25 Million |
-1.41% |
| 2004-12-31 | CN¥743.40 Million ≈ $108.78 Million |
+39.15% |
| 2003-12-31 | CN¥534.24 Million ≈ $78.18 Million |
+35.05% |
| 2002-12-31 | CN¥395.59 Million ≈ $57.89 Million |
+20.73% |
| 2001-12-31 | CN¥327.67 Million ≈ $47.95 Million |
+84.31% |
| 2000-12-31 | CN¥177.79 Million ≈ $26.02 Million |
-16.30% |
| 1999-12-31 | CN¥212.40 Million ≈ $31.08 Million |
-6.50% |
| 1998-12-31 | CN¥227.17 Million ≈ $33.24 Million |
+32.65% |
| 1997-12-31 | CN¥171.26 Million ≈ $25.06 Million |
+49.90% |
| 1996-12-31 | CN¥114.25 Million ≈ $16.72 Million |
+15.99% |
| 1995-12-31 | CN¥98.50 Million ≈ $14.41 Million |
-7.22% |
| 1994-12-31 | CN¥106.16 Million ≈ $15.53 Million |
-- |
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&… Read more